
Industry efforts to combat antimicrobial resistance are failing to keep pace with growing drug-resistant infections, a new report has found.
The pipeline of drugs aimed at tackling antimicrobial resistance (AMR) has shrunk by 35 percent over the past five years, according to a report by Access to Medicine Foundation, a Dutch independent non-profit working for medicine access in low and middle-income countries.